about
A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variabilityThe antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistanceMycobacterial shuttle vectors designed for high-level protein expression in infected macrophages.Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in BabiesTigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary DiseaseSusceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Thioridazine as Chemotherapy for Mycobacterium avium Complex DiseasesFailure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of TuberculosisThioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens.Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence.Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis.New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolatesIn vitro susceptibility testing and totally drug-resistant tuberculosis.Reply to “Pharmacokinetic Mismatch of Tuberculosis Drugs”.Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.Urine Colorimetry for Therapeutic Drug Monitoring of Pyrazinamide during Tuberculosis Treatment.Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosis.pH Conditions under Which Pyrazinamide Works in Humans.
P50
Q30275728-6B19C4D8-46A1-4671-A70E-E9444FBDC300Q35169089-D4E0E887-5FC4-4B18-8303-F257DE68AABEQ35364313-477C5258-C2FC-431C-BC0C-6640ED62BF2CQ35532853-51C276DA-2A87-4155-B266-401116CB77E3Q36172383-B2D9B44B-041A-4D75-8E08-71517DF6FF4BQ36277210-61101F0B-01E7-471A-AC96-178373A1E989Q36379388-2F58BBDC-92DD-4453-B71F-AA11BD801361Q36644647-10876BD5-74B4-4BBD-BB5E-38382ACA7B09Q36869913-6E24E49A-FD4F-4F51-A036-05E044B958DDQ36887811-F0720D9D-90B4-48F2-8B96-174665CE4621Q36888124-D8D709CE-FD7C-4E6F-91DA-B87ED4AF1D74Q36933441-7B9B250F-9A75-4B5E-AD4D-1581C5147F18Q37120152-BD340522-A9EE-4630-9F72-A80740823DF2Q37287641-2FBC1C77-21BE-4CD2-94A9-886A63CE302EQ37287787-86C8948C-6EB1-4FC7-AE1C-675248A7CFAEQ37287830-24D7A453-990F-4EF2-8EC8-657B2530EFA3Q37335803-28046ED9-C060-4AD9-B61B-2D8E942D99D2Q37339268-EFE3EF94-BBD7-4EEB-8051-0539305C0531Q37339276-3C01B24A-98B7-41DC-A62D-1C2202F816F6Q37339279-317B5652-5BF2-448E-B3F3-6A46EF1994CFQ37339287-015E0062-F843-4260-BBAB-8D4A4C0FE608Q37339290-BC794CA3-24A5-4791-82A4-0DABF6679D9BQ37915551-D407CE7E-36FF-40D4-AD9E-7F2542C0E9C9Q38803026-950DC6F8-F3C5-4EDD-8229-212ACBA2FFC1Q39632553-747CDD9A-0D86-4EFC-9B09-982DF6132CEFQ39715580-E7485464-B123-423B-82F8-F628853255B1Q40065397-6A8286F9-EA42-4018-BFDA-667E71F720CDQ40093562-82DBD6B9-7121-41FC-B069-88B19165B835Q40139991-5DF9FEAE-626F-4B9B-82BB-DF35F879B4A9Q40184248-0C241CE8-E05F-48A5-9232-7D27D98C9507Q40335980-20E2CA3D-2931-4DE1-B8C7-D9DFA1E52EDDQ41105755-55C74D10-91F8-406A-8511-38EB91A2801BQ42693542-F13E96AC-E160-4CF9-B1C9-B8317D9A5765Q45122942-C10FF749-A6B5-4913-ACAE-8AD7331BEF40Q45828861-7CBEABCF-A02B-4422-91CA-8F702A1D7306Q46169240-B6733BF6-BE8C-4528-87DF-F80D7E6CC260Q46427262-98E04CBB-8841-4C35-A123-4DE56F8A8C1DQ46482703-CC159E0F-1019-41B6-894D-9F9C3F605D42Q51127336-CCA754DB-3FFD-491C-A19E-21BA15A2B67BQ55226322-7D51AEFC-2C61-4E57-BCC1-AD3593128675
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Shashikant Srivastava
@ast
Shashikant Srivastava
@en
Shashikant Srivastava
@es
Shashikant Srivastava
@nl
Shashikant Srivastava
@sl
type
label
Shashikant Srivastava
@ast
Shashikant Srivastava
@en
Shashikant Srivastava
@es
Shashikant Srivastava
@nl
Shashikant Srivastava
@sl
prefLabel
Shashikant Srivastava
@ast
Shashikant Srivastava
@en
Shashikant Srivastava
@es
Shashikant Srivastava
@nl
Shashikant Srivastava
@sl
P106
P108
P31
P496
0000-0002-8786-8851